About the Author
My name is Mark Senak. I’m a lawyer and I work at the international communications firm FleishmanHillard in New York. For the past several years, I have been consulting with pharmaceutical and biologic companies that are engaged in the process of bringing new drugs to market. I have also worked extensively with an array of medical societies and patient organizations providing strategic communications counsel and media training.
Monthly Archives: February 2018
FDA’s Strategic Policy Roadmap, Part 3 – Improving Health Care, Access Issues and Public Health
In the last installment we looked at the first part of the Strategic Roadmap – Addiction which specifically focused on opioids and nicotine. However, the next part of the FDA Strategic Policy Roadmap is less specific and instead is focused … Continue reading
Posted in FDA Policy
Comments Off on FDA’s Strategic Policy Roadmap, Part 3 – Improving Health Care, Access Issues and Public Health
When Public Policy and Medical Science Are Misaligned
Two announcements last week were in startling contrast. One was a scientific development that moves the needle forward, the other a policy announcement that tries to pull it back. The first development came from Google AI researchers and a published … Continue reading
Posted in Current Affairs
Comments Off on When Public Policy and Medical Science Are Misaligned
Weekly Roundup 3.23.18
At least here in the mid-Atlantic region, the ground hog appears to have got it wrong, with a week that had quite moderate temperatures. In the herb garden, the chives have popped up, always a harbinger of Spring. I tried … Continue reading
Posted in Weekly Roundup
Comments Off on Weekly Roundup 3.23.18
Weekly Roundup 2.16.18
This week we had 70 degree temperatures and predictions of snow. It seems we are living in roller coaster times – at least for this month. For all the lovers out there, hope the Valentine’s Day was second to none. … Continue reading
Posted in Weekly Roundup
Comments Off on Weekly Roundup 2.16.18
FDA’s Strategic Policy Roadmap – Part 2 Addressing Addiction
With deaths rising each year, there is no question of the urgency that something needs to be done to address the opioid misuse epidemic in the United States. And in addition to mortality there are the lives touched by these … Continue reading
Posted in FDA Policy
Comments Off on FDA’s Strategic Policy Roadmap – Part 2 Addressing Addiction